Pure hepatocellular carcinoma originates from an ectopic liver nodule located in the pancreas

Braun, Marcin; Kuncman, Wojciech; Teresiński, Leszek; Kupnicki, Piotr; Jesionek-Kupnicka, Dorota; Kordek, Radzisław

doi:10.5114/wo.2017.72403

Cited by 10 publications

(19 citation statements)

References 13 publications

(36 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ectopic HCC is a rare malignancy, with morphology and immunohistochemistry similar to those of intrahepatic HCC. However, HCC development in ectopic liver is less commonly associated with risk factors for HCC arising in the mother liver, including hepatitis B virus or hepatitis C virus infection, alcohol abuse, and cirrhosis [2][3][4][5], which were all absent in our case.…”

Section: Discussionmentioning

confidence: 60%

“…To fully support the diagnosis of ectopic HCC, non-cancerous liver parenchyma should be identified around the HCC [6][7][8]. However, non-cancerous tissue is reported in only a few cases [2,5,9]. Since most cases show absence of non-cancerous tissue [10], it is suspected that the malignant cells have fully expanded and replaced the ectopic liver [5,6,10].…”

Section: Discussionmentioning

confidence: 99%

“…Ectopic livers are islands of normal liver parenchyma separated from the mother liver [1]. Their incidence is 0.23 and 0.47% in the largest autopsy and laparoscopic series, respectively [2]. Hepatocellular carcinoma (HCC) arising from ectopic liver tissue is rare, and the risk factors for HCC arising in the mother liver such as hepatitis B virus or hepatitis C virus infection, alcohol abuse, and cirrhosis are less relevant to ectopic HCC [2].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Unresectable Ectopic Hepatocellular Carcinoma Treated with Sorafenib

Takata

Tanaka

et al. 2020

Case Rep Gastroenterol

View full text Add to dashboard Cite

Ectopic hepatocellular carcinoma (HCC) is a rare malignancy, which manifests similar morphology and immunohistochemistry to intrahepatic HCC. Herein, we report a case of ectopic HCC in a 73-year-old male. The patient presented to our hospital with gradually progressing right lower abdominal pain, and enhanced computed tomography revealed multiple nodules in the peritoneum without intrahepatic mass. A diagnostic laparoscopy was performed, and the final pathology result confirmed that it was HCC. Additional laboratory tests showed elevated serum alpha-fetoprotein and protein induced by vitamin K absence-II (PIVKA-II) levels, suggesting our diagnosis. The patient received sorafenib, a tyrosine kinase inhibitor (TKI), for unresectable ectopic HCC. However, the tumor progressed, and because of tarry stools and hemorrhagic anemia, sorafenib was ceased after 7 months of therapy. One month after the cessation of sorafenib, the PIVKA-II level increased abruptly, and the patient died 1 year after diagnosis. 227The effective treatment for unresectable ectopic HCC is still unknown. Additional cases should be accumulated to determine the effect of TKI on ectopic HCC.

show abstract

Section: Discussionmentioning

confidence: 60%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Unresectable Ectopic Hepatocellular Carcinoma Treated with Sorafenib

Takata

Tanaka

et al. 2020

Case Rep Gastroenterol

View full text Add to dashboard Cite

show abstract

“…21 The radiological appearance of HCC in EL is less well characterized with less apparent arterial enhancement. 5,10,22 The present lesion demonstrated very subtle T2 hyperintensity and a very subtle hyperintense signal on diffusion weighted images that can be characteristic of HCC; however, other diagnoses such as pNET remained plausible.…”

Section: Discussionmentioning

confidence: 63%

“…7 The most common location for EL is the gallbladder and can range in size from millimeters to several centimeters, 8,9 whereas EL located in the pancreas is more uncommon. [10][11][12][13][14] The exact incidence of EL is unknown but thought to be *0.24% to 0.47% (Refs. 7,8,15,16 ).…”

Section: Discussionmentioning

confidence: 99%

Robotic Distal Pancreatectomy and Splenectomy for an Intrapancreatic Hepatocellular Carcinoma: A Case Report and Review of the Literature

Vining

Hsu

Schuitevoerder

et al. 2020

Journal of Pancreatic Cancer

View full text Add to dashboard Cite

Background: Liver parenchyma that resides outside of the normal hepatic confines is defined as accessory liver if in communication with the native biliary tree, or ectopic liver (EL) if it is not. EL can develop in a variety of tissues, including but not limited to the gallbladder, the hepatic ligaments, the pancreas, and retroperitoneum. EL has an increased propensity for malignant degeneration resulting in hepatocellular carcinoma (HCC). Presentation: A 67-year-old Korean male presented with epigastric discomfort and was found to have an elevation in his transaminases. Cross-sectional imaging demonstrated a 1.3 cm solid mass in the body of the pancreas with features concerning for either a pancreatic ductal adenocarcinoma or pancreatic neuroendocrine tumor. Subsequent endoscopic ultrasound and fine needle aspiration demonstrated cells of epithelial origin with hepatocellular differentiation. A robotic-assisted distal pancreatectomy and splenectomy was performed with final pathology demonstrating a well-differentiated HCC. Conclusions: EL with malignant degeneration resulting in HCC requires surgical excision. The majority of patients reported with EL resulting in HCC in the pancreas have had the tumors located in the body and tail. Therefore, definitive treatment requires distal pancreatectomy and splenectomy. Herein, we describe the presentation, workup, and definitive treatment of HCC arising in the pancreas.

show abstract

HOXA11‐AS regulates JAK‐STAT pathway by miR‐15a‐3p/STAT3 axis to promote the growth and metastasis in liver cancer

Wang

Zhang

et al. 2019

J of Cellular Biochemistry

View full text Add to dashboard Cite

Background HOMEOBOX A11 (HOXA11) antisense RNA (HOXA11‐AS), a newly identified long noncoding RNAs, is involved in the carcinogenic process of several human tumors. However, the role of HOXA11‐AS in liver cancer progression is not well understood. Materials and Methods This study used liver cancer tissues and cell lines (CSQT‐2 and HCCLM3) to explore the potential mechanism of HOXA11‐AS. Quantitative real‐time polymerase chain reaction and Western blot were applied to evaluate the bio‐molecules expression. Bioinformatics analysis, RNA pull down and luciferase report assay were applied to determine the molecules bind. MTT, transwell, and wound healing assay were used to measure the cell growth situation. Results HOXA11‐AS was highly expressed in liver cancer tissues and cell lines, which was closely related with poor prognosis in patients with liver cancer. HOXA11‐AS could act as a competing endogenous RNA for miR‐15a‐3p. Besides, miR‐15a‐3p negatively controlled its target molecule signal transducer and activator of transcription 3 (STAT3). Furthermore, a linear regression analysis and biological experiments showed a positive correlation between HOAX11‐AS and STAT3. Moreover, HOAX11‐AS overexpression activated the Janus kinase (JAK)‐STAT pathway and thus promoted the growth, migration, and invasion of liver cancer cells, which might be through regulating miR‐15a‐3p/STAT3 axis. Conclusion Our study suggested that HOAX11‐AS could regulate the JAK‐STAT signaling pathway by miR‐15a‐3p/STAT3 axis to promote the progression of liver cancer. Thus, HOXA11‐AS may be regarded as an effective biomarker with diagnostic, prognostic, and therapeutic potentials for liver cancer.

show abstract

Pure hepatocellular carcinoma originates from an ectopic liver nodule located in the pancreas

Cited by 10 publications

References 13 publications

Unresectable Ectopic Hepatocellular Carcinoma Treated with Sorafenib

Unresectable Ectopic Hepatocellular Carcinoma Treated with Sorafenib

Robotic Distal Pancreatectomy and Splenectomy for an Intrapancreatic Hepatocellular Carcinoma: A Case Report and Review of the Literature

HOXA11‐AS regulates JAK‐STAT pathway by miR‐15a‐3p/STAT3 axis to promote the growth and metastasis in liver cancer

Contact Info

Product

Resources

About